Europska Unija - švedski - EMA (European Medicines Agency)

sandoz gmbh - pemetrexed dinatriumhemipentahydrat - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignt pleuramesoteliom pemetrexed sandoz i kombination med cisplatin är indicerat för behandling av kemoterapi naiva patienter med unresectable malignt pleuramesoteliom. icke-småcellig lungcancer pemetrexed sandoz i kombination med cisplatin är indicerat för första linjens behandling av patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer andra än huvudsakligen skivepitelcancer histologi. pemetrexed sandoz är indicerat som monoterapi för underhåll behandling av lokalt avancerad eller metastaserad icke-småcellig lungcancer andra än huvudsakligen skivepitelcancer histologi hos patienter vars sjukdom inte har gått omedelbart efter platinum-baserad kemoterapi. pemetrexed sandoz är indicerat som monoterapi för andra linjens behandling av patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer andra än huvudsakligen skivepitelcancer histologi.

Europska Unija - švedski - EMA (European Medicines Agency)

merck europe b.v. - avelumab - neuroendokrina tumörer - andra antineoplastiska medel, monoklonala antikroppar - bavencio är indicerat som monoterapi för behandling av vuxna patienter med metastatisk merkel cellkarcinom (mcc). bavencio i kombination med axitinib är indicerat för första linjens behandling av vuxna patienter med avancerad njurcancer (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

Europska Unija - švedski - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

baxter medical ab - alanin; arginin; dikaliumfosfat; fenylalanin; glukosmonohydrat; glycin; histidin; isoleucin; kalciumkloriddihydrat; leucin; lysinhydroklorid; magnesiumkloridhexahydrat; metionin; natriumacetattrihydrat; natriumklorid; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - tyrosin 0,22 mg aktiv substans; leucin 4,02 mg aktiv substans; fenylalanin 3,08 mg aktiv substans; histidin 2,64 mg aktiv substans; valin 3,19 mg aktiv substans; treonin 2,31 mg aktiv substans; tryptofan 0,99 mg aktiv substans; isoleucin 3,3 mg aktiv substans; natriumacetattrihydrat 4,31 mg aktiv substans; prolin 3,74 mg aktiv substans; natriumklorid 2,24 mg aktiv substans; dikaliumfosfat 5,22 mg aktiv substans; magnesiumkloridhexahydrat 1,02 mg aktiv substans; alanin 11,39 mg aktiv substans; arginin 6,33 mg aktiv substans; glycin 5,67 mg aktiv substans; lysinhydroklorid 3,99 mg aktiv substans; serin 2,75 mg aktiv substans; metionin 2,2 mg aktiv substans; glukosmonohydrat 165 mg aktiv substans; kalciumkloriddihydrat 0,66 mg aktiv substans - kombinationer

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

baxter medical ab - alanin; arginin; dikaliumfosfat; fenylalanin; glukosmonohydrat; glycin; histidin; isoleucin; kalciumkloriddihydrat; leucin; lysinhydroklorid; magnesiumkloridhexahydrat; metionin; natriumacetattrihydrat; natriumklorid; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - kalciumkloriddihydrat 0,66 mg aktiv substans; glukosmonohydrat 220 mg aktiv substans; glycin 5,67 mg aktiv substans; arginin 6,33 mg aktiv substans; alanin 11,39 mg aktiv substans; lysinhydroklorid 3,99 mg aktiv substans; magnesiumkloridhexahydrat 1,02 mg aktiv substans; dikaliumfosfat 5,22 mg aktiv substans; natriumklorid 2,24 mg aktiv substans; prolin 3,74 mg aktiv substans; natriumacetattrihydrat 4,31 mg aktiv substans; isoleucin 3,3 mg aktiv substans; tryptofan 0,99 mg aktiv substans; serin 2,75 mg aktiv substans; metionin 2,2 mg aktiv substans; tyrosin 0,22 mg aktiv substans; leucin 4,02 mg aktiv substans; fenylalanin 3,08 mg aktiv substans; histidin 2,64 mg aktiv substans; valin 3,19 mg aktiv substans; treonin 2,31 mg aktiv substans - kombinationer

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

baxter medical ab - alanin; arginin; dikaliumfosfat; fenylalanin; glukosmonohydrat; glycin; histidin; isoleucin; kalciumkloriddihydrat; leucin; lysinhydroklorid; magnesiumkloridhexahydrat; metionin; natriumacetattrihydrat; natriumklorid; prolin; serin; treonin; tryptofan; tyrosin; valin - infusionsvätska, lösning - serin 5 mg aktiv substans; natriumklorid 1,18 mg aktiv substans; magnesiumkloridhexahydrat 1,02 mg aktiv substans; dikaliumfosfat 5,22 mg aktiv substans; arginin 11,5 mg aktiv substans; isoleucin 6 mg aktiv substans; natriumacetattrihydrat 6,8 mg aktiv substans; prolin 6,8 mg aktiv substans; lysinhydroklorid 7,25 mg aktiv substans; kalciumkloriddihydrat 0,66 mg aktiv substans; glukosmonohydrat 385 mg aktiv substans; glycin 10,3 mg aktiv substans; alanin 20,7 mg aktiv substans; metionin 4 mg aktiv substans; tyrosin 0,4 mg aktiv substans; leucin 7,3 mg aktiv substans; fenylalanin 5,6 mg aktiv substans; histidin 4,8 mg aktiv substans; valin 5,8 mg aktiv substans; treonin 4,2 mg aktiv substans; tryptofan 1,8 mg aktiv substans - kombinationer

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - deferasirox - filmdragerad tablett - 360 mg - deferasirox 360 mg aktiv substans

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - deferasirox - filmdragerad tablett - 90 mg - deferasirox 90 mg aktiv substans

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - deferasirox - filmdragerad tablett - 180 mg - deferasirox 180 mg aktiv substans

Švedska - švedski - Läkemedelsverket (Medical Products Agency)

teva sweden ab - deferasirox - filmdragerad tablett - 360 mg - deferasirox 360 mg aktiv substans